Pharmaceutical Strategies Group

Name

Pharmaceutical Strategies Group

Legal name

Pharmaceutical Strategies Group, LLC

Website

http://www.psgconsults.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmacy Benefit Consulting & Drug Cost Analytics

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Pharmacy Benefit Analytics, Reporting & Employer Consulting (HLAEAKAK)

akta.pro secondary industries

Pharmacy Benefit Management (PBM) & Formulary Management IT (HLACAKAD), Formulary Management & Clinical Pharmacy Programs (HLAEAKAA), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Pharmacy benefit consulting
• Specialty drug analytics
• PBM contract optimization
• Pharmacy claims analytics
• Gene therapy risk mitigation

Headquarters

HQ city

Plano

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmacy Benefits Consulting: PSG provides consulting services including audits, clinical optimization, contracting, government program services, market check, plan performance review, procurement and renewal, and PSG Modular PBA. Revenue is generated through professional consulting fees for advisory services to plan sponsors.
2. Artemetrx Analytics Platform: SaaS-based data and analytics platform providing dashboards, reports, and tools for specialty drug cost management. Revenue generated through software licensing and subscription fees to payers.
3. Market Research and Industry Reports: PSG publishes annual industry reports including Trends in Drug Benefit Design, State of Specialty Spend and Trend reports, and specialty drug benefits reports. Revenue through sponsored research and report sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Pharmaceutical Strategies Group (PSG) delivers independent pharmacy benefit consulting services and the proprietary Artemetrx analytics platform to healthcare payers (health plans, employers, health systems, and labor unions). Core engagements include pharmacy benefit audits, clinical optimization, PBM contracting, market check, plan performance review, procurement and renewal, government program services, and PSG Modular PBA. Artemetrx integrates pharmacy and medical claims data into dashboards and modules (including GeneCQ for gene therapy risk, SpecialtyCQ, Pricing Monitor, Rebate Monitor, and AI-enabled fraud, waste, and abuse detection) to provide transparency and actionable specialty drug cost management.

Product overview

Pharmaceutical Strategies Group (PSG) offers a platform-plus-modules architecture centered on the Artemetrx analytics platform, which integrates pharmacy and medical claims data for specialty drug cost management. The core Artemetrx platform is complemented by specialized modules including Core, Diagnostic, Extend, Plus, Pricing Monitor, Rebate Monitor, and SpecialtyCQ for comprehensive analytics. GeneCQ, a specialized module within Artemetrx, provides gene therapy risk mitigation through predictive analytics for high-cost cell and gene therapies. PSG also provides professional services including Pharmacy Benefits Consulting (Audits, Clinical Optimization, Contracting, Government Program Services, Market Check, Plan Performance Review, Procurement & Renewal), Implementation & Support, and Market Research (Custom Research, Industry Reports, Sponsorship). The company, an EPIC company, delivers drug cost savings and pharmacy intelligence to healthcare payers including employers, health plans, health systems, and labor unions.

Differentiator

Problem solved

Functional benefit

Brands

• Artemetrx: PSG's proprietary SaaS data and analytics platform integrating pharmacy and medical claims data for specialty drug cost management.
• GeneCQ
• SpecialtyCQ
• Rebate Monitor
• Pricing Monitor
• PSG Modular PBA

Products and services

• Artemetrx Analytics Platform PSG's proprietary data and analytics platform integrating pharmacy and medical claims data for specialty drug cost management. Provides web-based dashboards, reports, and tools delivering transparency and actionable interventions to improve program performance for healthcare payers (health plans, employers, health systems, and labor unions).
• Artemetrx GeneCQ Gene therapy risk mitigation solution within Artemetrx that uses actuarial predictive models on integrated pharmacy and medical claims data to quantify member-level financial exposure for one-time, curative, non-oncology cell and gene therapies, enabling payers to budget and reserve against high-cost gene therapy claims.
• Artemetrx AI-Enabled Fraud, Waste, and Abuse Detection Attribute-driven AI model built within Artemetrx that identifies potential FWA and assigns risk scores by evaluating patterns across prescriber behaviors, pharmacy dispensing trends, diagnosis and therapy alignment, member utilization profiles, and cost and quantity dynamics.
• Pharmacy Benefits Consulting Comprehensive independent pharmacy benefit consulting services for plan sponsors covering Audits, Clinical Optimization, Contracting, Government Program Services, Market Check, Plan Performance Review, and Procurement & Renewal. Delivered by PSG's consulting team to health plans, employers, health systems, and labor unions.
• PSG Modular PBA Modular Pharmacy Benefit Administration solution providing flexible, à la carte PBA consulting services for plan sponsors seeking targeted pharmacy benefit administration support outside of full-service PBM contracts.
• Implementation & Support PBM transition and implementation services ensuring complete and thorough implementation of pharmacy benefit programs, including specialized services for ongoing operational support and best-practice PBM transitions.
• Market Research Industry-leading pharmacy management research services including Custom Research, Industry Reports (Trends in Drug Benefit Design Report, Artemetrx State of Specialty Spend and Trend Report), Sponsorship opportunities, and Research Participation programs for plan sponsors and industry stakeholders.

Quantifiable outcome

• $10.7B drug cost savings generated over last two years
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Partnerships

One partnership is on record.

• TranscarentcoreStrategic or Co-development Partner · 9 June 2026Transcarent sponsored PSG's 2026 Trends in Drug Benefit Design Report. The partnership highlights shared perspectives on pharmacy transparency, accountability, and employer benefits strategy. Transcarent's President Snezana Mahon, PharmD, provided commentary on employer drug benefit considerations.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Mercer: Mercer (a Marsh McLennan business) is one of the largest health and benefits consulting firms globally, with a dedicated PBM consulting and audit practice serving employers and health plans. Competes with PSG on enterprise PBM advisory engagements.
• Aon: Aon's Health & Benefits practice offers PBM consulting, contract optimization, and specialty drug management advisory to large employers. Its scale and broker relationships make it a formidable competitor for PSG's employer segment.
• Willis Towers Watson (WTW): WTW provides pharmacy benefit consulting as part of its broader Health & Benefits services, including PBM procurement, audit, and clinical program advisory. Overlaps with PSG in employer and health plan engagements.
• Segal Group: Segal is an independent benefits and human resources consulting firm with a pharmacy benefit consulting practice serving public sector, multiemployer, and corporate plan sponsors. Competes with PSG for labor union and large employer clients.
• OptumRx (UnitedHealth Group): OptumRx is the largest PBM in the US, owned by UnitedHealth Group. While a PBM rather than a consulting firm, its scale, integrated data assets, and employer-direct contracting capability define the competitive backdrop against which PSG's independent advisory value is judged.

Emerging players

• EmpiRx Health: EmpiRx Health is a PBM that combines pharmacy benefit management with clinical consulting and analytics for self-funded employers. Its hybrid consulting/PBM model overlaps with PSG's value proposition in the mid-market employer segment.
• SmithRx: SmithRx is a transparent PBM targeting small and mid-sized self-funded employers with pass-through pricing. While a PBM rather than a consultant, its direct contracting model reduces the scope of work traditionally outsourced to firms like PSG.
• Capital Rx: Capital Rx operates a transparent, technology-led PBM (Judi) and offers pharmacy benefit consulting-adjacent services. Its technology-forward model targets the same employer pain points PSG addresses (PBM opacity), making it an emerging competitive threat.

Direct peers

• RxBenefits: RxBenefits provides PBM optimization and contracting services primarily to employers and benefits brokers, with a model very similar to PSG: independent advisory combined with analytics. It is the closest direct competitor in employer-focused PBM consulting.
• PayerAlly: PayerAlly is a pharmacy benefit consulting firm that provides PBM audits, contract negotiation, and specialty drug strategy for employers and unions. Closely matches PSG's consulting services portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/psgconsults
• LinkedInlinkedin.com/company/psgconsults

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaceutical Strategies Group